Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

National University Health System (NUHS)

Status: Not yet enrolling

Conditions: Cardiovascular Diseases; Non-Alcoholic Fatty Liver Disease; Metabolic Syndrome

Treatments: Behavioral: Digital wearable and AI-human symbiotic lifestyle intervention

Study type: Observational

Funder types: Other

Identifiers

NCT06211868

RESET

Details and patient eligibility

About

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 40-70 years old
• ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion criteria

• Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
• Limited life expectancy
• Other ongoing unstable medical conditions
• Pregnant women

Trial design

3,000 participants in 2 patient groups

Observational cohort

Randomised cohort

Treatment:

Behavioral: Digital wearable and AI-human symbiotic lifestyle intervention